LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

Accueil・Liste d'Actions・AnaptysBio Inc

AnaptysBio Inc

Fermé

SecteurSoins de santé

51.39 1.86

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

49.8

Max

52.53

Chiffres clés
By Trading Economics
Revenu	-102M -53M
Ventes	-83M 26M
BPA	-1.843
Marge bénéficiaire	-206.934
Employés	104
EBITDA	-102M -34M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+43.93% upside

Dividendes
By Dow Jones
Prochains Résultats	4 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-430M 1.5B
Ouverture précédente	49.53
Clôture précédente	51.39

Sentiment de l'Actualité

By Acuity

93%

319 / 344 Classement par Healthcare

AnaptysBio Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

8 juin 2026, 22:20 UTC

Acquisitions, Fusions, Rachats

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

8 juin 2026, 15:41 UTC

Principaux Mouvements du Marché

American Battery Shares Jump on Energy Department Victory

8 juin 2026, 23:46 UTC

Market Talk

Nikkei May Rebound After Monday's Selloff -- Market Talk

8 juin 2026, 23:37 UTC

Market Talk

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

8 juin 2026, 23:25 UTC

Market Talk

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

8 juin 2026, 23:25 UTC

Market Talk

Global Equities Roundup: Market Talk

8 juin 2026, 21:57 UTC

Acquisitions, Fusions, Rachats

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

8 juin 2026, 21:56 UTC

Acquisitions, Fusions, Rachats

Salesforce Agrees to Buy m3ter

8 juin 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

8 juin 2026, 19:22 UTC

Market Talk

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

8 juin 2026, 19:01 UTC

Market Talk

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

8 juin 2026, 18:52 UTC

Market Talk

Global Energy Roundup: Market Talk

8 juin 2026, 18:52 UTC

Market Talk

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

8 juin 2026, 18:17 UTC

Market Talk

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

8 juin 2026, 17:32 UTC

Market Talk

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

8 juin 2026, 17:29 UTC

Market Talk

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

8 juin 2026, 17:29 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 juin 2026, 16:55 UTC

Acquisitions, Fusions, Rachats

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

8 juin 2026, 16:54 UTC

Acquisitions, Fusions, Rachats

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

8 juin 2026, 16:40 UTC

Market Talk

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

8 juin 2026, 16:31 UTC

Market Talk

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

8 juin 2026, 16:27 UTC

Market Talk

Mexican Inflation Seen Easing in May -- Market Talk

8 juin 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8 juin 2026, 16:03 UTC

Acquisitions, Fusions, Rachats

Orange Bought Stake From Lorca

8 juin 2026, 16:01 UTC

Acquisitions, Fusions, Rachats

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

8 juin 2026, 16:01 UTC

Acquisitions, Fusions, Rachats

Orange Acquires 100% Ownership of MasOrange

8 juin 2026, 15:58 UTC

Market Talk

Global Equities Roundup: Market Talk

8 juin 2026, 15:58 UTC

Market Talk

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

8 juin 2026, 15:55 UTC

Market Talk

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

8 juin 2026, 15:41 UTC

Market Talk

Gold Falls Below 200-Day Moving Average -- Market Talk

Comparaison

Variation de prix

AnaptysBio Inc prévision

Objectif de Prix

By TipRanks

43.93% hausse

Prévisions sur 12 Mois

Moyen 72.5 USD 43.93%

Haut 93 USD

Bas 50 USD

Basé sur 9 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

9 ratings

Achat

Maintien

Vente

Basé sur 9 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

319 / 344Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.